Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors

In This Article:

Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced non-brokered private placement of 2,500,000 common shares (each a "Share") at $0.10 per Share for total gross proceeds of $250,000 (the "Offering"). Concurrently, with the closing of the Offering, the Company announces closing of its acquisition of 160 Ethereum cryptocurrency ("ETH") in consideration for the issuance of 7,840,000 common shares (the "ETH Acquisition").

The Offering and ETH Acquisition remains subject to final acceptance from the Canadian Securities Exchange. All securities issued in connection with the Offering and ETH Acquisition will be subject to a statutory hold period expiring four months plus one day from closing.

The Company intends to use the net proceeds of the Offering and the ETH Acquisition for general working capital purposes.

The securities being offered have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons or persons in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Appointment of Hunter Jordan

The Company is pleased to announce that it has appointed Hunter Jordan to its Board of Directors.

Hunter is a VP at a private real estate firm, specializing in global real estate operating company investments. In this role, he leads strategic initiatives to establish and scale platforms while optimizing governance structures. Hunter began his career at PwC, earning his CPA designation, and has worked across multiple sectors and regions.

The Company also announces that it has granted a total of 200,000 stock options to certain directors, officers and consultants of the Company. Each option is exercisable to purchase one common share of the Company at an exercise price of $0.20 for a period of 5 years.

About Moss Genomics Inc.

Moss is a biotechnology company utilizing Artificial Intelligence, Genomic, Microbiome, and a diverse array of health data to develop unique and innovative health solutions. By integrating blockchain and advanced treasury strategies, Moss seeks to leverage modern advancements in technology in the life sciences industry.